A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

a study on Melanoma Skin Cancer/Melanoma Breast Cancer Hepatocellular Carcinoma Liver Cancer Transitional Cell Carcinoma Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Kidney Cancer Renal Cell Carcinoma Colorectal Cancer Lung Cancer Non-Small Cell Lung Cancer Endometrial Cancer Solid Tumor

Summary

for people ages 18 years and up (full criteria)
at San Diego, California and other locations
study started
estimated completion:

Description

Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Official Title

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Keywords

Melanoma Breast Carcinoma Hepatocellular Carcinoma Urothelial Carcinoma Squamous Cell Carcinoma of the Head and Neck Renal Cell Carcinoma Colorectal Carcinoma Non-small Cell Lung Carcinoma Gastric or Gastroesophageal Junction Adenocarcinoma Endometrial Carcinoma DUET-2 Triple Negative Breast Cancer Hepatocellular Urothelial Cancer Bladder Cancer Renal Cell Cancer Head and Neck Cancer MSI-high Colorectal Cancer MSI-high Endometrial Cancer Non-small Cell Lung Cancer Gastric Cancer Gastroesophageal Junction Cancer Carcinoma Carcinoma, Squamous Cell Adenocarcinoma Carcinoma, Hepatocellular Carcinoma, Renal Cell Breast Neoplasms Lung Neoplasms Carcinoma, Transitional Cell Head and Neck Neoplasms Carcinoma, Non-Small-Cell Lung Endometrial Neoplasms Colorectal Neoplasms Esophageal Neoplasms XmAb20717

Eligibility

You can join if…

Open to people ages 18 years and up

  • Histologically or cytologically confirmed advanced solid tumors including:
  • Melanoma (excluding uveal melanoma);
  • Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC);
  • Hepatocellular carcinoma;
  • Urothelial carcinoma;
  • Squamous cell carcinoma of the head and neck;
  • Renal cell carcinoma (clear cell predominant type);
  • Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma;
  • Non-small cell lung carcinoma;
  • Gastric or gastroesophageal junction adenocarcinoma
  • All subjects' cancer must have progressed after treatment with standard therapies or have no appropriate available therapies.
  • Have available archival formalin-fixed paraffin-embedded block(s) containing tumor or at least 20 unstained slides containing tumor.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You CAN'T join if...

  • Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.
  • Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.
  • Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent).
  • Subjects currently receiving other anticancer therapies.
  • Treatment with any other anticancer therapy within 2 weeks of the start of study drug(i.e., other immunotherapy, chemotherapy, radiation therapy, etc.).
  • A life-threatening (Grade 4) immune-mediated adverse event related to prior immunotherapy.
  • Failure to recover from any immune-related toxicity from prior cancer therapy to ≤Grade 1.
  • Failure to recover from any other toxicity (other than immune-related toxicity)related to previous anticancer treatment to ≤ Grade 2.
  • Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only;psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs).
  • Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted).
  • Receipt of an organ allograft.
  • Treatment with antibiotics within 14 days prior to first dose of study drug.

Locations

  • University of California San Diego Moores Cancer Center accepting new patients
    San Diego California 92093-0698 United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute accepting new patients
    Los Angeles California 90048 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Xencor, Inc.
ID
NCT03517488
Phase
Phase 1
Study Type
Interventional
Last Updated